Management of Paget's disease of bone

Osteoporos Int. 2020 May;31(5):827-837. doi: 10.1007/s00198-019-05259-1. Epub 2019 Dec 17.


Paget's disease is a progressive focal bone condition which can result in pain, low quality of life, deformity and other complications. Disease progression can be halted with potent bisphosphonates, resulting in improvement in both quality of life and pain, and normalisation of scintigraphy, plain radiographs and bone histology. Zoledronate has transformed the treatment of Paget's disease, producing sustained remissions in almost all patients. Thus, it is now possible to normalise bone cell activity and prevent disease progression at low cost, with one or two intravenous injections of zoledronate, greatly reducing follow-up costs. Patients with Paget's disease who are symptomatic or at risk of complications should have the opportunity to reap these therapeutic benefits. Potent bisphosphonates are highly effective in halting disease progression in Paget's disease, but guidelines disagree about treatment indications. The efficacy, safety and low cost of zoledronate recommend its use in any patient who is symptomatic or judged to be at risk of complications from Paget's disease.

Keywords: Bisphosphonates; Paget’s disease of bone.

Publication types

  • Review

MeSH terms

  • Bone and Bones
  • Diphosphonates / therapeutic use
  • Humans
  • Osteitis Deformans* / drug therapy
  • Quality of Life
  • Zoledronic Acid / therapeutic use


  • Diphosphonates
  • Zoledronic Acid